Trial reportBreast (Edinburgh, Scotland)2026
Association of mobile application information on multidisciplinary therapy and treatment compliance in early-stage breast cancer: A prospective multicenter randomized phase III study.
Trial report in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05921331 (Mobile Medical Application on Adjuvant Therapy Compliance and Quality of Life in Patients With Early Breast Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mobile Medical Application on Adjuvant Therapy Compliance and Quality of Life in Patients With Early Breast Cancer: a Multicentric, Open-labeled, Randomized Controlled Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultidisciplinary therapy (MDT) can improve early breast cancer outcome, while its treatment completion rate is critical. This study aimed to evaluate the association of a mobile health application (RJBC-APP) information on MDT and its treatment adherence, compared with standard clinical management.
methodsThe RJBC-APP study is a prospective, multicenter, randomized, phase 3 clinical trial that enrolled patients with early-stage breast cancer after MDT for adjuvant treatment. Eligible patients were randomized at a 1:1 ratio into two groups: the RJBC-APP group (the mobile-based App) and the control group. The primary endpoint was 12-month adjuvant treatment compliance rate. Secondary endpoints included treatment adherence rates at 3, 6, and 24 months.
resultsBetween October 2023 and July 2024, a total of 508 patients were randomized, and 496 were included in the final analysis (249 [50.2%] in the RJBC-APP group and 247 [49.8%] in the control group). The 12-month treatment compliance rate was 85.5% (95% confidence interval [CI]: 81.1%-90.0%) in the RJBC-APP group and 81.4% (95% CI: 76.5%-86.3%) in the control group (P = 0.212). Exploratory subgroup analysis revealed that RJBC-APP usage was associated with a higher treatment completion rate in patients aged ≤50 years (85.0% vs. 78.2%), whereas no comparable effect in older patients (86.2% vs. 86.0%) (P for interaction = 0.043). Additionally, the RJBC-APP improved the 3-month treatment completion rate compared with control group (93.2% vs. 87.0%, P = 0.022).
conclusionsThe RJBC-APP did not improve 12-month adjuvant therapy compliance rate for early-stage breast cancer patients receiving MDT. While exploratory subgroup analysis indicated a potential benefit of the RJBC-APP on compliance in younger patients or in the short-term period, these should be considered as hypothesis-generating and warrant further investigation.
trial registrationcinicalTrials.gov Identifier: NCT05921331.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.